AU2003205855A1 - Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist - Google Patents

Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist

Info

Publication number
AU2003205855A1
AU2003205855A1 AU2003205855A AU2003205855A AU2003205855A1 AU 2003205855 A1 AU2003205855 A1 AU 2003205855A1 AU 2003205855 A AU2003205855 A AU 2003205855A AU 2003205855 A AU2003205855 A AU 2003205855A AU 2003205855 A1 AU2003205855 A1 AU 2003205855A1
Authority
AU
Australia
Prior art keywords
formulation
inhalation
adrenoreceptor agonist
beta
glucocorticoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003205855A
Other languages
English (en)
Inventor
Keith Biggadike
Paul Jones
Jeremy John Payne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27732220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2003205855(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/066,961 external-priority patent/US6537983B1/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2003205855A1 publication Critical patent/AU2003205855A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003205855A 2002-02-04 2003-02-04 Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist Abandoned AU2003205855A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/066,961 2002-02-04
US10/066,961 US6537983B1 (en) 2001-04-07 2002-02-04 Anti-inflammatory androstane derivatives
PCT/GB2003/000485 WO2003066033A1 (en) 2002-02-04 2003-02-04 Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist

Publications (1)

Publication Number Publication Date
AU2003205855A1 true AU2003205855A1 (en) 2003-09-02

Family

ID=27732220

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003205855A Abandoned AU2003205855A1 (en) 2002-02-04 2003-02-04 Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist

Country Status (7)

Country Link
EP (1) EP1471895B2 (enExample)
JP (1) JP2005523268A (enExample)
AT (1) ATE396716T1 (enExample)
AU (1) AU2003205855A1 (enExample)
DE (1) DE60321311D1 (enExample)
ES (1) ES2305438T5 (enExample)
WO (1) WO2003066033A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
AU2011315315B2 (en) 2010-10-12 2016-08-18 Cipla Limited Pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95590A (en) † 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
GB9903759D0 (en) † 1999-02-18 1999-04-14 Novartis Ag Organic compounds
CA2417826A1 (en) * 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
WO2002070490A1 (en) * 2001-03-08 2002-09-12 Glaxo Group Limited Agonists of beta-adrenoceptors
EP1370521B1 (en) * 2001-03-22 2007-12-19 Glaxo Group Limited Formanilide derivatives as beta2-adrenoreceptor agonists
UA77656C2 (en) † 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent

Also Published As

Publication number Publication date
EP1471895A1 (en) 2004-11-03
JP2005523268A (ja) 2005-08-04
ES2305438T3 (es) 2008-11-01
WO2003066033A1 (en) 2003-08-14
ATE396716T1 (de) 2008-06-15
DE60321311D1 (de) 2008-07-10
ES2305438T5 (es) 2012-06-05
EP1471895B1 (en) 2008-05-28
EP1471895B2 (en) 2012-03-14

Similar Documents

Publication Publication Date Title
MY139577A (en) Anti-inflammatory androstane derivative
SE0104334D0 (sv) Therapeutic agents
NO20084005L (no) Aminderivater
AP1422A (en) 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent.
NO20055854L (no) (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
TW200508180A (en) Therapeutic agents
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
GEP20074055B (en) Nicotinamide derivatives useful as pde4 inhibitors
MXPA05012840A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
TW200619199A (en) 3-carbamoyl-2-pyridone derivatives
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
MY129796A (en) Novel anti-inflammatory androstane derivatives
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
NO20062983L (no) Sulfonamid-derivater for behandling av sykdommer
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
IL149586A0 (en) Pyrimidine derivatives as selective inhibitors of cox-2
ATE479433T1 (de) Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
BR0307071A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
TW200607508A (en) Powder formulations for inhalation, comprising enantiomerically pure beta agonists
EA200800783A1 (ru) Композиция тразодона для введения один раз в день
TR200101028T2 (tr) 2,3-Diikameli piridin türevi, bunun hazırlanmasında kullanılan proses, bunu içeren farmasötik terkip ve ara maddesi
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
AU2003205855A1 (en) Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase